Tianjin Weijie Pharmaceutical is an API manufacturer based in China. It holds 14 active US drug master files across a filed portfolio of 14 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 29 November 2024 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3005526021 |
| Molecule | Regulators | Docs |
|---|---|---|
| Abiraterone | US FDA | 1 |
| Ambrisentan | US FDA | 1 |
| Belinostat | US FDA | 1 |
| Bexarotene | US FDA | 1 |
| Cabazitaxel | US FDA | 1 |
| Diethylstilbestrol | US FDA | 1 |
| Eletriptan | US FDA | 1 |
| Midodrine | US FDA | 1 |
| Ospemifene | US FDA | 1 |
| Pomalidomide | US FDA | 1 |
| Rivaroxaban | US FDA | 1 |
| Terbinafine | US FDA | 1 |
| Teriflunomide | US FDA | 1 |
| Vilazodone | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Tianjin Weijie Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free